Skip to NavigationSkip to content

Alexander Hardy returns to Genentech as new CEO

Published on 28/01/19 at 12:18pm

Genetech, the biotech subsidiary of Swiss firm Roche, has named its new CEO, revealing that Alexander Hardy will be returning to the company to lead its operations.

Hardy originally joined Genentech in 2005, and during his time with the company he has held a number of senior management roles, including the management of patient access services and commercial operations across a range of disciplines such as influenza, neuroscience, and HER2-positive breast cancer.

He currently serves as Head of Product Strategy, previously becoming head of Asia Pacific operations in 2014. Hardy will assume the role on 1 March this year, succeeding current CEO Bill Anderson, who himself became Chief Executive of Roche on 1 January.  

“We’re delighted to welcome Alexander back to Genentech as Chief Executive Officer,” remarked Anderson. “He brings significant global expertise in the delivery of breakthrough medicines and a deep connection to the company culture. I look forward to seeing Genentech’s scientific excellence, employee experience and dedication to patients thrive under his leadership.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches